Yvonne H. Sada

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu, Richard S. Finn, Julien Edeline et al. · The Lancet Oncology · 2018 · 2.5K citations

Open-label Phase 2, Hepatology, Medicine +8

Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans Is Associated With Nonalcoholic Fatty Liver Disease

Sahil Mittal, Hashem B. El‐Serag, Yvonne H. Sada et al. · Clinical Gastroenterology and Hepatology · 2015 · 627 citations · Full text

Metabolic Associated Steatohepatitis, Hepatology, Nonalcoholic Fatty Liver Disease +11

Temporal Trends of Nonalcoholic Fatty Liver Disease–Related Hepatocellular Carcinoma in the Veteran Affairs Population

Sahil Mittal, Yvonne H. Sada, Hashem B. El‐Serag et al. · Clinical Gastroenterology and Hepatology · 2014 · 257 citations · Full text

Hepatology, Nonalcoholic Fatty Liver Disease, Temporal Trends +13

Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: A United States cohort

Sahil Mittal, Fasiha Kanwal, Jun Ying et al. · Journal of Hepatology · 2016 · 142 citations · Full text

Epidemiology, Hepatology, Cancer Epidemiology +11

Utility of Adjuvant Chemotherapy After Neoadjuvant Chemoradiation and Esophagectomy for Esophageal Cancer

Bryan M. Burt, Shawn S. Groth, Yvonne H. Sada et al. · Annals of Surgery · 2016 · 102 citations